nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—COMT—attention deficit hyperactivity disorder	0.519	0.611	CbGaD
Methyldopa—ADRA2A—attention deficit hyperactivity disorder	0.331	0.389	CbGaD
Methyldopa—COMT—Enzymatic degradation of Dopamine by monoamine oxidase—MAOA—attention deficit hyperactivity disorder	0.0106	0.0844	CbGpPWpGaD
Methyldopa—DDC—Serotonin and melatonin biosynthesis—TPH2—attention deficit hyperactivity disorder	0.00957	0.0759	CbGpPWpGaD
Methyldopa—COMT—Clearance of dopamine—SLC6A3—attention deficit hyperactivity disorder	0.00911	0.0723	CbGpPWpGaD
Methyldopa—COMT—Clearance of dopamine—MAOA—attention deficit hyperactivity disorder	0.0077	0.061	CbGpPWpGaD
Methyldopa—ADRA2A—Adrenaline signalling through Alpha-2 adrenergic receptor—ADRA2C—attention deficit hyperactivity disorder	0.00736	0.0584	CbGpPWpGaD
Methyldopa—COMT—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—attention deficit hyperactivity disorder	0.00416	0.033	CbGpPWpGaD
Methyldopa—DDC—Amine-derived hormones—TPH2—attention deficit hyperactivity disorder	0.00378	0.0299	CbGpPWpGaD
Methyldopa—COMT—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—attention deficit hyperactivity disorder	0.00351	0.0278	CbGpPWpGaD
Methyldopa—ADRA2A—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.00306	0.0242	CbGpPWpGaD
Methyldopa—DDC—Dopamine metabolism—COMT—attention deficit hyperactivity disorder	0.0027	0.0214	CbGpPWpGaD
Methyldopa—DDC—Dopamine metabolism—MAOA—attention deficit hyperactivity disorder	0.00268	0.0213	CbGpPWpGaD
Methyldopa—DDC—Nicotine Activity on Dopaminergic Neurons—CHRNA4—attention deficit hyperactivity disorder	0.00261	0.0207	CbGpPWpGaD
Methyldopa—DDC—Biogenic Amine Synthesis—COMT—attention deficit hyperactivity disorder	0.00241	0.0191	CbGpPWpGaD
Methyldopa—DDC—Biogenic Amine Synthesis—MAOA—attention deficit hyperactivity disorder	0.00239	0.019	CbGpPWpGaD
Methyldopa—COMT—Dopamine metabolism—MAOA—attention deficit hyperactivity disorder	0.00238	0.0189	CbGpPWpGaD
Methyldopa—DDC—Nicotine Activity on Dopaminergic Neurons—DRD3—attention deficit hyperactivity disorder	0.00235	0.0186	CbGpPWpGaD
Methyldopa—DDC—Nicotine Activity on Dopaminergic Neurons—DRD4—attention deficit hyperactivity disorder	0.00228	0.0181	CbGpPWpGaD
Methyldopa—DDC—forebrain—attention deficit hyperactivity disorder	0.00224	0.136	CbGeAlD
Methyldopa—DDC—Nicotine Activity on Dopaminergic Neurons—DRD2—attention deficit hyperactivity disorder	0.00213	0.0169	CbGpPWpGaD
Methyldopa—COMT—Biogenic Amine Synthesis—MAOA—attention deficit hyperactivity disorder	0.00212	0.0168	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—SLC6A3—attention deficit hyperactivity disorder	0.00163	0.0129	CbGpPWpGaD
Methyldopa—COMT—forebrain—attention deficit hyperactivity disorder	0.00148	0.09	CbGeAlD
Methyldopa—DDC—midbrain—attention deficit hyperactivity disorder	0.00148	0.0899	CbGeAlD
Methyldopa—DDC—Parkinsons Disease Pathway—SLC6A3—attention deficit hyperactivity disorder	0.00135	0.0107	CbGpPWpGaD
Methyldopa—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC9A9—attention deficit hyperactivity disorder	0.00134	0.0106	CbGpPWpGaD
Methyldopa—COMT—cardiovascular system—attention deficit hyperactivity disorder	0.00125	0.0761	CbGeAlD
Methyldopa—ADRA2A—Adrenaline,noradrenaline inhibits insulin secretion—ADRA2C—attention deficit hyperactivity disorder	0.00123	0.00978	CbGpPWpGaD
Methyldopa—DDC—nervous system—attention deficit hyperactivity disorder	0.00121	0.0739	CbGeAlD
Methyldopa—DDC—central nervous system—attention deficit hyperactivity disorder	0.00117	0.0712	CbGeAlD
Methyldopa—ADRA2A—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.00108	0.00857	CbGpPWpGaD
Methyldopa—ADRA2A—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.00106	0.0084	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—ADRA2C—attention deficit hyperactivity disorder	0.000987	0.00782	CbGpPWpGaD
Methyldopa—COMT—midbrain—attention deficit hyperactivity disorder	0.000977	0.0594	CbGeAlD
Methyldopa—DDC—brain—attention deficit hyperactivity disorder	0.000928	0.0565	CbGeAlD
Methyldopa—Levonordefrin—ADRA2C—attention deficit hyperactivity disorder	0.000911	0.117	CrCbGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.000909	0.00721	CbGpPWpGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.000891	0.00706	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.000868	0.00688	CbGpPWpGaD
Methyldopa—ADRA2A—Adrenaline,noradrenaline inhibits insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.000851	0.00675	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (z) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000844	0.00669	CbGpPWpGaD
Methyldopa—COMT—nervous system—attention deficit hyperactivity disorder	0.000803	0.0489	CbGeAlD
Methyldopa—ADRA2A—Adrenaline,noradrenaline inhibits insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.000779	0.00617	CbGpPWpGaD
Methyldopa—COMT—central nervous system—attention deficit hyperactivity disorder	0.000773	0.0471	CbGeAlD
Methyldopa—COMT—cerebellum—attention deficit hyperactivity disorder	0.000756	0.046	CbGeAlD
Methyldopa—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000753	0.0458	CbGeAlD
Methyldopa—COMT—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.000665	0.00527	CbGpPWpGaD
Methyldopa—Droxidopa—ADRA2C—attention deficit hyperactivity disorder	0.000642	0.0822	CrCbGaD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.000642	0.00509	CbGpPWpGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.000617	0.00489	CbGpPWpGaD
Methyldopa—COMT—brain—attention deficit hyperactivity disorder	0.000614	0.0374	CbGeAlD
Methyldopa—DDC—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000611	0.00484	CbGpPWpGaD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.0006	0.00475	CbGpPWpGaD
Methyldopa—ADRA2A—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.000597	0.00473	CbGpPWpGaD
Methyldopa—ADRA2A—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.000578	0.00458	CbGpPWpGaD
Methyldopa—L-DOPA—DRD5—attention deficit hyperactivity disorder	0.000573	0.0734	CrCbGaD
Methyldopa—ADRA2A—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.000561	0.00445	CbGpPWpGaD
Methyldopa—ADRA2A—Regulation of insulin secretion—ADRA2C—attention deficit hyperactivity disorder	0.000549	0.00435	CbGpPWpGaD
Methyldopa—Norepinephrine—ADRA2C—attention deficit hyperactivity disorder	0.00054	0.0692	CrCbGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00054	0.00428	CbGpPWpGaD
Methyldopa—Dopamine—DRD5—attention deficit hyperactivity disorder	0.000533	0.0682	CrCbGaD
Methyldopa—DDC—Amino acid and derivative metabolism—TPH2—attention deficit hyperactivity disorder	0.000526	0.00417	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000525	0.00416	CbGpPWpGaD
Methyldopa—ADRA2A—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.000523	0.00414	CbGpPWpGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.000502	0.00398	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.000499	0.00395	CbGpPWpGaD
Methyldopa—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000498	0.0303	CbGeAlD
Methyldopa—Epinephrine—ADRA2C—attention deficit hyperactivity disorder	0.00049	0.0628	CrCbGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.000488	0.00387	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000488	0.00387	CbGpPWpGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.000486	0.00385	CbGpPWpGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.000472	0.00374	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000444	0.00352	CbGpPWpGaD
Methyldopa—ADRA2A—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.000439	0.00348	CbGpPWpGaD
Methyldopa—ADRA2A—Integration of energy metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000432	0.00342	CbGpPWpGaD
Methyldopa—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000409	0.0249	CbGeAlD
Methyldopa—DDC—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.000399	0.00316	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.000399	0.00316	CbGpPWpGaD
Methyldopa—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000394	0.024	CbGeAlD
Methyldopa—Levonordefrin—ADRA2A—attention deficit hyperactivity disorder	0.000389	0.0498	CrCbGaD
Methyldopa—DDC—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.000386	0.00306	CbGpPWpGaD
Methyldopa—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000385	0.0234	CbGeAlD
Methyldopa—COMT—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000382	0.00303	CbGpPWpGaD
Methyldopa—ADRA2A—Regulation of insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.000379	0.003	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.000375	0.00297	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000367	0.00291	CbGpPWpGaD
Methyldopa—ADRA2A—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000366	0.0029	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000355	0.00282	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000354	0.00281	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.000349	0.00277	CbGpPWpGaD
Methyldopa—ADRA2A—Regulation of insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.000347	0.00275	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000341	0.0027	CbGpPWpGaD
Methyldopa—Dopamine—COMT—attention deficit hyperactivity disorder	0.000336	0.0431	CrCbGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.000335	0.00266	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000317	0.00251	CbGpPWpGaD
Methyldopa—ADRA2A—brain—attention deficit hyperactivity disorder	0.000313	0.019	CbGeAlD
Methyldopa—ADRA2A—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000308	0.00244	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000305	0.00242	CbGpPWpGaD
Methyldopa—ADRA2A—Regulation of insulin secretion—SNAP25—attention deficit hyperactivity disorder	0.000303	0.0024	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000302	0.00239	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000299	0.00237	CbGpPWpGaD
Methyldopa—ADRA2A—Integration of energy metabolism—CACNB2—attention deficit hyperactivity disorder	0.000298	0.00236	CbGpPWpGaD
Methyldopa—L-DOPA—DRD4—attention deficit hyperactivity disorder	0.000293	0.0375	CrCbGaD
Methyldopa—COMT—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000293	0.00232	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000291	0.0023	CbGpPWpGaD
Methyldopa—Droxidopa—ADRA2A—attention deficit hyperactivity disorder	0.000274	0.0351	CrCbGaD
Methyldopa—ADRA2A—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000273	0.00216	CbGpPWpGaD
Methyldopa—Dopamine—DRD4—attention deficit hyperactivity disorder	0.000273	0.0349	CrCbGaD
Methyldopa—COMT—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000272	0.00216	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000267	0.00212	CbGpPWpGaD
Methyldopa—Dopamine—MAOA—attention deficit hyperactivity disorder	0.000254	0.0325	CrCbGaD
Methyldopa—L-DOPA—DRD3—attention deficit hyperactivity disorder	0.000253	0.0324	CrCbGaD
Methyldopa—L-DOPA—DRD1—attention deficit hyperactivity disorder	0.000248	0.0318	CrCbGaD
Methyldopa—COMT—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000243	0.00192	CbGpPWpGaD
Methyldopa—ADRA2A—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.000238	0.00189	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.000236	0.00187	CbGpPWpGaD
Methyldopa—Dopamine—DRD3—attention deficit hyperactivity disorder	0.000235	0.0301	CrCbGaD
Methyldopa—Dopamine—DRD1—attention deficit hyperactivity disorder	0.000231	0.0295	CrCbGaD
Methyldopa—Norepinephrine—ADRA2A—attention deficit hyperactivity disorder	0.000231	0.0295	CrCbGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000225	0.00178	CbGpPWpGaD
Methyldopa—Dopamine—SLC6A3—attention deficit hyperactivity disorder	0.000219	0.028	CrCbGaD
Methyldopa—Epinephrine—ADRA2A—attention deficit hyperactivity disorder	0.000209	0.0268	CrCbGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000209	0.00165	CbGpPWpGaD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000209	0.00165	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000205	0.00162	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000204	0.00162	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000203	0.00161	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000179	0.00142	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000175	0.00139	CbGpPWpGaD
Methyldopa—L-DOPA—DRD2—attention deficit hyperactivity disorder	0.000175	0.0224	CrCbGaD
Methyldopa—Norepinephrine—DRD2—attention deficit hyperactivity disorder	0.000175	0.0224	CrCbGaD
Methyldopa—Dopamine—SLC6A4—attention deficit hyperactivity disorder	0.000164	0.0209	CrCbGaD
Methyldopa—Dopamine—DRD2—attention deficit hyperactivity disorder	0.000163	0.0208	CrCbGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000159	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000153	0.00121	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000142	0.00112	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00014	0.00111	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000136	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000133	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000133	0.00106	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.00013	0.00103	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000124	0.000985	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000124	0.000982	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000122	0.000965	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000121	0.000963	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00012	0.000953	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000117	0.000925	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000115	0.000913	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000115	0.00091	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000112	0.000884	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000109	0.000862	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000108	0.000858	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000106	0.000841	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000106	0.000841	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000104	0.000826	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000101	0.0008	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	9.87e-05	0.000782	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TPH2—attention deficit hyperactivity disorder	9.66e-05	0.000766	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.66e-05	0.000766	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	9.56e-05	0.000758	CbGpPWpGaD
Methyldopa—DDC—Metabolism—DPYD—attention deficit hyperactivity disorder	9.5e-05	0.000753	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	9.28e-05	0.000736	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	9.25e-05	0.000733	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.83e-05	0.0007	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	8.64e-05	0.000685	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TPH2—attention deficit hyperactivity disorder	8.57e-05	0.00068	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.57e-05	0.00068	CbGpPWpGaD
Methyldopa—COMT—Metabolism—DPYD—attention deficit hyperactivity disorder	8.44e-05	0.000669	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	8.08e-05	0.000641	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.84e-05	0.000622	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.72e-05	0.000612	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.7e-05	0.00061	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.54e-05	0.000598	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.51e-05	0.000596	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.35e-05	0.000583	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.28e-05	0.000577	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.07e-05	0.00056	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.07e-05	0.00056	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.99e-05	0.000554	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.86e-05	0.000543	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.85e-05	0.000543	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.58e-05	0.000522	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.53e-05	0.000517	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.16e-05	0.000488	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.05e-05	0.00048	CbGpPWpGaD
Methyldopa—DDC—Metabolism—COMT—attention deficit hyperactivity disorder	5.85e-05	0.000464	CbGpPWpGaD
Methyldopa—DDC—Metabolism—MAOA—attention deficit hyperactivity disorder	5.81e-05	0.000461	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.23e-05	0.000414	CbGpPWpGaD
Methyldopa—COMT—Metabolism—MAOA—attention deficit hyperactivity disorder	5.16e-05	0.000409	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.94e-05	0.000391	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.81e-05	0.000381	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.75e-05	0.000376	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.61e-05	0.000365	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.57e-05	0.000362	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.25e-05	0.000337	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.15e-05	0.000329	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.13e-05	0.000327	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.11e-05	0.000326	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.04e-05	0.000321	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.99e-05	0.000317	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.97e-05	0.000314	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.86e-05	0.000306	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.73e-05	0.000296	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.72e-05	0.000295	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.63e-05	0.000287	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	3.41e-05	0.00027	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.41e-05	0.00027	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.38e-05	0.000268	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	3.35e-05	0.000266	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.12e-05	0.000247	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.8e-05	0.000222	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.72e-05	0.000216	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.61e-05	0.000207	CbGpPWpGaD
Methyldopa—DDC—Metabolism—EP300—attention deficit hyperactivity disorder	2.51e-05	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.45e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.37e-05	0.000188	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.28e-05	0.000181	CbGpPWpGaD
Methyldopa—COMT—Metabolism—EP300—attention deficit hyperactivity disorder	2.23e-05	0.000177	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.21e-05	0.000175	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	2.18e-05	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.14e-05	0.00017	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	2.06e-05	0.000164	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	2.05e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.4e-05	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	8.85e-06	7.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.4e-06	5.87e-05	CbGpPWpGaD
